Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
Shiwen Peng,
Louise Ferrall,
Stephanie Gaillard,
Chenguang Wang,
Wei-Yu Chi,
Chuan-Hsiang Huang,
Richard B. S. Roden,
T.-C. Wu,
Yung-Nien Chang,
Chien-Fu Hung
Affiliations
Shiwen Peng
Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Louise Ferrall
Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Stephanie Gaillard
Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA
Chenguang Wang
Department of Oncology Biostatistics, The Johns Hopkins University, Baltimore, Maryland, USA
Wei-Yu Chi
Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Chuan-Hsiang Huang
Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Persistent expression of high-risk human papillomavirus (HPV) E6 and E7 is an obligate driver for several human malignancies, including cervical cancer, wherein HPV16 and HPV18 are the most common types. PD-1 antibody immunotherapy helps a subset of cervical cancer patients, and its efficacy might be improved by combination with active vaccination against E6 and/or E7.
